U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07159126) titled 'A Study of DS3610a in Participants With Advanced Solid Tumor' on Aug. 29.
Brief Summary: This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Metastatic Solid Tumors
Intervention:
DRUG: DS3610a
Participants will receive DS3610a at the target dose. Treatment will continue until radiographic disease progression, as determined by the investigator, or until another reason for discontinuation of trial intervention occurs.
Recruitment Status: N...